You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 21, 2024

Details for Patent: 7,528,143

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,528,143 protect, and when does it expire?

Patent 7,528,143 protects INREBIC and is included in one NDA.

This patent has forty-nine patent family members in twenty-seven countries.

Summary for Patent: 7,528,143

Patent landscape, scope, and claims:

Title:	Bi-aryl meta-pyrimidine inhibitors of kinases
Abstract:	The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases. ##STR00001##
Inventor(s):	Noronha; Glenn (Oceanside, CA), Mak; Chi Ching (San Diego, CA), Cao; Jianguo (San Diego, CA), Renick; Joel (San Diego, CA), McPherson; Andrew (San Diego, CA), Zeng; Binqi (San Diego, CA), Pathak; Ved P. (San Diego, CA), Lohse; Daniel L. (San Diego, CA), Hood; John D. (San Diego, CA), Soll; Richard M. (San Diego, CA)
Assignee:	TargeGen, Inc. (San Diego, CA)
Application Number:	11/588,638
Patent Claim Types: see list of patent claims	Composition; Compound;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 7,528,143

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol-myers	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes	7,528,143	⤷ Subscribe	Y	Y			⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,528,143

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1951684	⤷ Subscribe	301104	Netherlands	⤷ Subscribe
European Patent Office	1951684	⤷ Subscribe	122021000023	Germany	⤷ Subscribe
European Patent Office	1951684	⤷ Subscribe	LUC00204	Luxembourg	⤷ Subscribe
European Patent Office	1951684	⤷ Subscribe	PA2021509	Lithuania	⤷ Subscribe
European Patent Office	1951684	⤷ Subscribe	2021C/513	Belgium	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.